Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome

Trial Profile

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Hereditary nephritis
  • Focus Registrational; Therapeutic Use
  • Acronyms CARDINAL
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 01 Dec 2022 Results evaluating the safety and efficacy of bardoxolone methyl in patients with Alport syndrome, published in the Clinical Journal of The American Society of Nephrology: CJASN
    • 28 Feb 2022 According to a Reata Pharmaceuticals media release, On February 25, 2022, the company received a complete response letter from the FDA with respect to its review of NDA for bardoxolone in the treatment of patients with chronic kidney disease caused by Alport syndrome.
    • 08 Dec 2021 According to a Reata Pharmaceuticals media release, Kyowa Kirin submitted an NDA in Japan to the Ministry of Health, Labour and Welfare for bardoxolone for improvement of renal function in patients with Alport syndrome, and the application is currently under review.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top